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Abstract
Background: Millions of individuals with malaria-like fevers purchase drugs from private retailers, but
artemisinin-based combination therapies (ACTs), the only effective treatment in regions with high levels of
resistance to older drugs, are rarely obtained through these outlets due to their relatively high cost. To
encourage scale up of ACTs, the Affordable Medicines Facility – malaria is being launched to subsidize their
price. The Government of Tanzania and the Clinton Foundation piloted this subsidized distribution model in
two Tanzanian districts to examine concerns about whether the intervention will successfully reach poor, rural
communities.
Methods: Stocking of ACTs and other antimalarial drugs in all retail shops was observed at baseline and in four
subsequent surveys over 15 months. Exit interviews were conducted with antimalarial drug customers during each
survey period. All shops and facilities were georeferenced, and variables related to population density and
proximity to distribution hubs, roads, and other facilities were calculated. To understand the equity of impact,
shops stocking ACTs and consumers buying them were compared to those that did not, according to geographic
and socioeconomic variables. Patterning in ACT stocking and sales was evaluated against that of other common
antimalarials to identify factors that may have impacted access. Qualitative data were used to assess motivations
underlying stocking, distribution, and buying disparities.
Results: Results indicated that although total ACT purchases rose from negligible levels to nearly half of total
antimalarial sales over the course of the pilot, considerable geographic variation in stocking and sales persisted and
was related to a variety of socio-spatial factors; ACTs were stocked more often in shops located closer to district
towns (p<0.01) and major roads (p<0.01) and frequented by individuals of higher socioeconomic status (p<0.01).
However, other antimalarial drugs displayed similar patterning, indicating the existence of underlying disparities in
access to antimalarial drugs in general in these districts.
Conclusions: As this subsidy model is scaled up across multiple countries, these results confirm the potential for
increased ACT usage but suggest that additional efforts to increase access in remote areas will be needed for the
scale-up to have equitable impact.
Trial registration: Current Controlled Trials ISRCTN39125414.
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Background
It is estimated that only 37% of patients with malaria
seek treatment in the public sector [1], while millions
purchase drugs through private outlets. However, arte-
misinin-based combination therapies (ACTs), the only
effective malaria treatment in regions with high levels of
resistance to older antimalarial drugs, are very rarely
obtained through these private retailers [2]. ACTs are
typically sold at retail prices 20-40 times those of com-
mon alternatives such as amodiaquine and sulphadox-
ine-pyrimethamine (SP), making them prohibitively
expensive for the 40-60% of febrile individuals seeking
treatment from private vendors like pharmacies or drug
shops. The widespread development of resistance to
cheaper antimalarial drugs means that a majority of
individuals suffering from malaria worldwide are not
receiving effective treatment.
To encourage scale-up of ACT coverage, the global
malaria community is launching the Affordable Medi-
cines Facility – malaria (AMFm) to subsidize the price
of ACTs at the point of production for distribution in
the public and private sectors. However, concerns
remain about whether the intervention will succeed in
reaching poor, rural communities [3]. To provide evi-
dence to inform these discussions, the Government
of Tanzania and the Clinton Foundation tested the
model through a pilot program in two rural Tanzanian
districts.
The pilot demonstrated that ACTs could indeed lead
to high uptake [4]. Stocking of ACTs in retail drug
shops increased from 0/133 in August 2007 to 109/151
(72.2%) a year later. As importantly, these drugs were
sold at or below the target retail price; interviewed cus-
tomers paid an average price of $0.58 during the study
period, an amount in line with the cost of other com-
mon antimalarial drugs. The effect was striking; while
only 1% of antimalarial consumers purchased ACTs
before initiation of the subsidy, that fraction increased
to about 40% a year later.
Despite these gains, the final survey following 14 months
of implementation revealed that 60% of antimalarial drug
shop customers still were purchasing alternatives to these
heavily subsidised, effective ACTs. This population of indi-
viduals receiving ineffective medications can be divided
into those who purchased antimalarial or antipyretic drugs
at a shop that did not carry ACTs, and second, those who
shopped where ACTs were available, but who chose to
purchase an antipyretic or another antimalarial instead. By
the end of the study period, over a quarter of shops in the
study districts continued not to stock ACTs. Of customers
buying drugs at shops that did stock ACTs, 44% chose to
buy a different antimalarial. With failure rates of upwards
of 42% for drugs like amodiaquine [5], it is essential to
understand why some shops never stocked ACTs during
the subsidy and why some customers did not buy them
even when given the option.
This analysis investigates drivers of subsidized ACT
stocking and sales at the shop level and ACT purchase
at the individual level through spatial analysis. Observed
patterning in ACT stocking and sales is compared
against that of other common antimalarial drugs to
identify factors that may be specifically impacting access
to the subsidized drugs. To help contextualize geo-
graphic patterns, qualitative data are presented to assess
rationales underlying stocking, distribution, and buying
disparities.
Methods
Study population
The intervention was conducted in two rural districts of
Tanzania: Maswa in Shinyanga region and Kongwa in
Dodoma region. These districts were comparable in
terms of key indicators including population per health
facility, employment, prevalence of private drug shops,
and bed net ownership. Recent surveys found 30%
malaria parasite prevalence in children 6-59 months in
Shinyanga, compared to 13% in Dodoma [6]. Socioeco-
nomic status (SES) of households in both districts is
below the national average as evidenced by comparison
of key assets such as housing materials, toilet facilities,
and availability of electricity [7]. Private sector shops –
particularly the part II drug stores called duka la dawa
baridi (DLDB) – provide the majority of fever treatment
in Tanzania [8]. DLDB are required to be staffed by an
individual with at least one year of health training, and
are only allowed to sell over-the-counter (OTC) medi-
cines, although research has shown that both of these
requirements are often not met [9]. Drug shops pur-
chase supplies from regional drug wholesalers or phar-
macies, which buy from other wholesalers or importers
[8,10].
In 2006, Tanzania switched its national guidelines for
first-line malaria treatment to ACT, specifically arte-
mether-lumefantrine (AL), with free distribution begin-
ning in the public and non-governmental organization
(NGO) sectors in December of that year. ACTs are
classified as prescription-only medication, and currently
are only consistently available in health facilities and
registered part I pharmacies. The previous first-line
treatment, SP, was adopted in 2001 but rapidly lost
effectiveness [11].
Details of the subsidy design are reported elsewhere
[4]. In brief, artemether-lumefantrine, the recommended
first-line ACT in Tanzania, was purchased from the
manufacturer, Novartis, and sold to a pharmaceutical
wholesaler in Dar es Salaam at an average of $0.11 per
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dose. The wholesaler received no instructions other than
to sell the ACTs to drug shops in the two intervention
districts according to its standard practices, and it was
made clear that the wholesaler would not be monitored
or held accountable for its pricing, stocking, or other
practices. To reflect potential information, education,
and communication interventions that will accompany
the AMFm, additional activities included a one-day
training of DLDB attendants focused on malaria symp-
toms and ACT dispensing and dosing, and Population
Services International activities emphasizing the impor-
tance and availability of ACTs, including local radio
advertisements, wall paintings, and themed cultural
shows. A suggested retail price of 300, 600, 900, and
1200 Tanzanian Shillings was marked on ACT packages
distributed in Kongwa, but not in Maswa.
Data collection
Retail audits [12] were used to collect data on stocking
and sales of antimalarial drugs in all the 226 DLDB that
existed in the two districts over the course of the pro-
ject. DLDB were initially identified through Tanzania
Food and Drug Authority records, with unregistered
DLDB captured through discussions with local infor-
mants and systematic physical reconnaissance through-
out each district. All DLDB were georeferenced using
hand-held Garmin Etrex global positioning system units.
Each audit involved visiting a DLDB twice at a one
month interval. Collectors recorded the stock level of all
antimalarial drugs present during each visit, and a short
questionnaire was administered to the owner or atten-
dant to determine the amount of each product newly
purchased and disposed of (e.g., due to expiry or
damage) during the previous four weeks. Sales volumes
were then calculated by comparing stock levels between
the two visits and adding purchases and subtracting dis-
posals. Data collectors also visited all public and NGO
health facilities in each survey period to review ACT
stocks and dispensing records. As with DLDB, all
locations were georeferenced.
Exit interviews were used to collect information on
shoppers and their antimalarial drug choices. Data col-
lectors positioned themselves near a DLDB and
remained there for the full business day. Collectors
maintained some distance from the DLDB to avoid dis-
rupting normal business. All customers emerging were
approached and asked to answer a short questionnaire
about the products bought. Those purchasing drugs for
malaria or fever were asked about the primary reason
they selected the particular antimalarial or antipyretic
drug they purchased, and the brand of the product was
visually verified. Interviewees were asked a series of
questions about 53 types of household assets including
ownership of commodities, presence of electricity, and
housing materials, in-line with the 2003-04 Tanzania
HIV/AIDS Indicator Survey [13]. Both retail audits and
exit interviews were conducted a total of four times
after the pilot subsidy began in October: November
2007, and March, August, and November 2008.
Finally, qualitative interviews with shop owners and
wholesale distributors were conducted in November
2008 following the pilot program to contextualize the
quantitative results. Thirty-four DLDB storeowners and
four wholesale distributors were interviewed using a
semi-structured interview guide. Storeowners were ran-
domly selected from six DLDB groupings constructed
according to the number of neighboring shops within
1 km. Distributors were selected by asking the national
wholesaler to identify the principal agents it used to
supply ACTs in the intervention districts. The struc-
tured interviews probed about ACT availability, stock-
ing, pricing, and profitability, and supply of and demand
for antimalarial drugs including the subsidized ACT.
Interviews were mostly conducted in Kiswahili, tran-
scribed, and then translated into English. Qualitative
data were coded and analyzed using MaxQDA; the cod-
ing scheme was developed based on the key research
questions and themes that were generated by the
interviews.
Variable creation
ArcGIS v9.3 was used to generate spatial variables that
could be used to describe the relative remoteness of
retail DLDB and their proximity to other DLDB and
public facilities. A shapefile of all wards (a “ward” is the
4th administrative boundary in Tanzania) created by the
International Livestock Research Institute (ILRI) and
National Census Bureau (http://www.ilri.org/gis/) was
used to identify the population density for the ward in
which each DLDB was located. An additional ILRI sha-
pefile of major roads produced from LANDSAT images
was also used.
Euclidean distance from each DLDB to the nearest
major road was calculated, as was average distance to
the three nearest neighboring DLDB and the number of
neighboring DLDB within 1 km. Similarly, the average
distance to the three nearest public or NGO facilities
and the number within 1 km were computed along with
the distance to the nearest facility that was ever found
to be stocked with any ACTs and the nearest facility
found to be always stocked with at least one dose of
ACTs at each survey. The number of surveys in which
the nearest facility to each DLDB was stocked was
counted. Since DLDB might open or close during the
study period, the number of surveys in which each
DLDB was found to be open for business was counted
as an additional variable that might relate to the health
and viability of the shop.
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To estimate the real-world distance from each DLDB
to the town where the regional wholesaler was located
and from which ACT distribution initiated – in Kongwa,
this hub was the town of Dodoma, while in Maswa it
was Maswa Town – road-weighted distance was calcu-
lated as the sum of two figures: shortest-path distance
from the hub to the road nearest the DLDB, plus
straight-line distance from that road to the DLDB
weighted six times as heavily as on-road distance to
account for the meandering nature and poorer condition
of these roads and therefore the slower speed of these
segments of the trip [14]. The weight of 6 was selected
based on an assumption that travel by major road could
proceed up to the speed limit of 120kph while travel off
these roads could achieve a maximum of 20kph; other
weights were employed for comparison and did not qua-
litatively change results (data not shown). Finally, Nor-
malized Difference Vegetation Index (NDVI) values
calculated from satellite imagery [15], which represent
the amount of visible green vegetation, were given to
each DLDB as a measure of the environment in which
each shop was located. Log transformations were used
to normalize variables that appeared heavily skewed
after visual inspection of histograms.
An index of SES was calculated through a principal
component analysis of the 53 household asset variables
collected in exit interviews [16]. SES was rescaled so
that the shopper with the lowest principal component
score (and thus lowest status) received a value of 0 and
the shopper with the highest score a value of 100. High-
est education status attained was considered as a
numerical variable ranging from 0 (no formal education)
to 6 (university).
Statistical analysis
All analyses were computed using the SAS System v 9.2.
Stocking patterns. DLDB were divided according to
whether or not they were ever found to stock or have
sold ACTs during any of the four audits following initia-
tion of the subsidy. DLDB that were found to stock or
sell ACTs were compared to those that did not in regards
to geographic characteristics using t-tests (Satterthwaite
tests were used when variances were unequal and pooled
tests otherwise) or chi-square tests as appropriate. For
example, the average population density at which DLDB
stocking or selling ACTs were located was compared to
the average for those DLDB not stocking or selling ACTs
using a t-test, while the relationship between stocking of
ACTs and other antimalarial drugs was compared with a
chi-square test. Each of the variables that were found to
differ significantly between stocking and not stocking
shops in these comparisons then were entered jointly
into multivariate logistic regression to determine whether
associations were independent.
To examine whether differences in ACT stocking were
unique to that subsidized antimalarial drug and its dis-
tribution network, these same methods were used to
compare stocking of any SP or sulfamethoxypyrazine-
pyrimethamine (SMP) product, as well as specifically for
the two most commonly sold drug brands besides the
subsidized ACT product, the generic drugs Orodar (SP
manufactured by Elys Chemical Industries Ltd of Kenya)
and Malafin (SMP manufactured by Shelys Pharmaceuti-
cals of Tanzania). Chi-square tests were used to examine
whether stocking of ACTs and these other common
antimalarial drugs was correlated.
Buying patterns. To examine the population of shop-
pers reached by the subsidized ACT distribution
network, the characteristics of individuals shopping at
DLDB that stocked and did not stock ACTs were exam-
ined through the same statistical methods. Individual-
level variables included SES, age, education, and gender
of the shopper, the age and gender of the individual for
whom the drug was being purchased, and rationale for
buying the chosen drug.
Finally, analysis was restricted to the set of DLDB that
were found to have stocked or sold ACTs, and the char-
acteristics of individuals who chose to purchase ACTs
when they were available at those DLDB were compared
to the characteristics of those who purchased other anti-
malarial drugs. To examine whether different character-
istics of individuals were independent predictors of the
drug purchased, these variables were entered into a mul-
tivariate regression model using the GENMOD proce-
dure in SAS with a REPEATED statement to adjust for
the correlation between customers shopping at the same
store.
Results
Stocking patterns
Significant turnover in the existence of DLDB was
observed, with 73 DLDB (32.3%) available for observa-
tion in all periods and 52 in only one.
ACT stocking. Of the 226 DLDB ever surveyed in the
two districts, 47 (20.8%) were never found to stock or
sell ACTs. 179 (79.2%) were found to stock or sell
ACTs during at least one of the four survey periods
from November 2007 through November 2008, with the
percent stocking increasing steadily over the study per-
iod (Table 1). For 93 (52.0%) of these 179 DLDB, ACT
sales comprised less than 50% of antimalarial products
sold while 86 (38.1%) had ACTs comprise at least 50%
of all antimalarial sales (Figure 1). The percentage of
DLDB never stocking ACT was higher in Kongwa than
in Maswa (28.3% versus 15.7% respectively) (c2=5.25,
1 d.f., p=0.02).
On average, DLDB stocking or selling ACTs were less
remote than DLDB that never stocked or sold ACTs
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Table 1 Characteristics of drug shops and their customers over the four post-subsidy surveys
November 2007 March 2008 August 2008 November 2008
Shops 138 146 151 166
Newly opened * 36 32 20
Reopened * * 9 18
Closed * 28 36 23
Stocking ACT 77 (55.8%) 87 (59.6%) 107 (70.9%) 121 (72.9%)
Stocking branded
generic SP
110 (79.7%) 96 (65.8%) 116 (76.8%) 129 (77.7%)
Stocking Orodar 85 (61.6%) 62 (42.5%) 82 (54.3%) 88 (53.0%)
Stocking Malafin 30 (21.7%) 26 (17.8%) 52 (34.4%) 65 (39.2%)
Customers surveyed
buying drug for malaria
or fever
443 415 746 972
Buying antimalarial 292 (65.9%) 290 (69.9%) 455 (61.0%) 572 (58.9%)
Buying ACT 90 (20.3%) 129 (31.1%) 200 (26.8%) 225 (23.2%)
Buying branded
generic SP
88 (19.9%) 76 (18.3%) 158 (21.2%) 209 (21.5%)
Figure 1 Maps of retail DLDB in (a) Kongwa and (b) Maswa.
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(Figure 2). For example, the 47 DLDB that were never
found to stock or sell ACTs in any of the four surveys
were located in wards with average population density of
91.2 people/km2, compared to 113.0/km2 for DLDB that
stocked. Never-stocking DLDB on average were located
significantly farther from roads, the district town, and
other DLDB and public facilities, and had much lower
total antimalarial sales (all p<0.01). DLDB that never
stocked were found to be open for business during an
average of 1.8 surveys compared to 2.8 for DLDB that
ever stocked ACTs (t=-5.93, 224 d.f., p<0.01).
In multivariate logistic regression, three variables, the
number of surveys in which the shop was observed
(adjusted odds ratio = 1.63, [95% confidence interval =
1.03-2.59]), the distance from the shop to the main
town (adj OR = 0.04 [0.01-0.16]), and the average dis-
tance to the three nearest neighboring shops (adj OR =
0.61 [0.46-0.81]), remained independent predictors of
whether a shop ever stocked ACTs (all p<0.01) with the
same direction of association as described above. No
other variable in Figure 2 demonstrated a statistically
significant association with stocking when controlling
for these variables.
SP stocking. Only 15/226 DLDB (6.6%) were never
found to stock or sell SP or SMP (hereafter referred to
as “SP”). Stocking was significantly and positively
Figure 2 Distributions of geographic variables according to DLDB stocking status. The distributions of selected geographic variables are
shown for DLDB that were and were not found to stock or sell ACTs, Malafin, and Orodar. Stores stocking and not stocking each product were
compared using t-tests, and statistically significant differences (a=0.01) are starred.
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associated with the number of surveys in which a DLDB
was observed, total antimalarial sales, and negatively
with the average distance to the three nearest public
health facilities (all p<0.01). In multivariate logistic
regression, none of the variables depicted in Figure 2
demonstrated statistically significant associations with
SP stocking when controlling for the number of surveys
in which a shop was observed.
During the four survey periods, retail audits indicated
that Orodar and Malafin were purchased 22,003 and
8,016 times, respectively, compared to 37,698 treatments
of ACT. There were 49 DLDB (21.7%) that never
stocked or sold Orodar, and these DLDB differed signifi-
cantly from the 177 that did in that they were, on aver-
age, surveyed less frequently and had lower total sales
(Figure 2). However, no statistically significant pattern-
ing in geographic variables was evident (with a=0.01).
There were 106 DLDB that never stocked or sold
Malafin (46.9%), with patterns in Malafin stocking and
sales extremely similar to those observed for ACTs (Fig-
ure 2). The same variables demonstrated significant
associations, and in the same direction, as with ACTs
with two exceptions: DLDB stocking Malafin were sig-
nificantly closer to a public health or NGO facility
always stocking ACTs, while those stocking ACTs were
not, and the public health facility nearest Malafin-stock-
ing DLDB tended to stock ACTs more frequently than
was the case for other shops (both p<0.01).
Joint stocking. Stocking of ACTs and SP in DLDB was
not independent (c2=14.99, 1 d.f., p<0.01). Of the 211
DLDB that stocked SP at any time during the follow-up
period, 82.0% also stocked ACTs. In comparison, only
40.0% of the 15 shops not stocking SP had ACTs avail-
able. This pattern held true for each of the individual SP
products as well; 86.4% of the 177 DLDB stocking Oro-
dar also stocked ACTs compared to 53.0% of those that
did not, while 92.5% of the 120 DLDB stocking Malafin
also stocked ACTs compared to 64.2% of those that did
not. 59.3% of shops stocking Orodar also stocked Mala-
fin, compared to 30.6% of shops that did not (c2=12.70,
1 d.f., p<0.01).
Consumer characteristics
Customer characteristics by stocking status of DLDB.
Individuals shopping at DLDB that never stocked or
sold ACTs tended to have less education, be of lower
SES, and be buying the drugs for slightly older indivi-
duals than shoppers at DLDB stocking ACTs (Table 2).
The differences in shopper characteristics were consis-
tent when comparing only those shopping in November
2007 with those in November 2008. All three of these
variables remained independently associated with stock-
ing status in multivariate regression; a one-level increase
in the shopper’s education was associated with adjusted
OR = 1.48 (1.18-1.84) for shopping at a DLDB stocking
ACTs, while a one-unit increase in SES was associated
with adjusted OR = 2.23 (1.65-3.01) and each additional
year of the recipient’s age was associated with adjusted
OR = 0.97 (0.97-0.99). These relationships were
unchanged by additionally controlling for the spatial
characteristics of the DLDB locations at which indivi-
duals were shopping. No differences in age or education
were evident between individuals shopping at DLDB
with different stocking or sales of SP; however, as with
ACTs, individuals shopping at DLDB never stocking SP
had lower SES than those shopping at stores that did.
Customer characteristics by drug choice. Table 3
depicts factors associated with whether or not an indivi-
dual purchased an antimalarial or an antipyretic and an
ACT or a non-ACT at DLDB that stocked them. Indivi-
duals buying antimalarials were older, buying drugs for
younger recipients, wealthier, and better educated than
were individuals buying antipyretics. When entered into
multivariate models controlling for correlation between
customers at the same store, the customer’s age (adj OR =
1.06 [1.04-1.09]), education (adj OR = 1.32 [1.08-1.61]),
and the age of the intended recipient (adj OR = 0.95 [0.93-
0.97]) remained independent predictors, but the custo-
mer’s SES did not (adj OR = 0.95 [0.79 – 1.14]). ACTs
were purchased by older individuals (adj OR = 1.03 [1.01-
1.06]) for younger recipients (adj OR = 0.98 [0.96-1.00])
than were other antimalarials, but no differences in sex of
the purchaser or recipient were evident (Table 3).
Table 2 Comparison of shopper characteristics according to the stocking status of DLDB at which they shopped
Never stocked
ACTs
Stocked ACTs Never stocked
SP
Stocked SP
Variable n Mean(SD) n Mean(SD) t (df), p n Mean(SD) n Mean(SD) t (df), p
Age of intended recipient
(years)
215 23.77(12.95) 1648 21.11(13.85) 2.67 (1861), p=0.01 46 21.37(12.85) 1817 21.42(13.80) -0.02 (1861), p=0.98
Age of purchaser (years) 289 30.43(8.70) 2270 30.11(8.47) 0.60 (2557), p=0.55 53 30.21(7.40) 2506 30.15(8.51) 0.05 (2557), p=0.96
Education level of
purchaser (0-6)
225 1.81(0.96) 1966 2.21(1.06) -5.38 (2189), p<0.01 47 1.94(1.07) 2144 2.17(1.05) -1.50 (2189), p=0.13
Socioeconomic status
of purchaser
289 26.96(11.61) 2274 35.22(16.19) -10.83^ (444), p<0.01 53 26.63(7.98) 2510 34.45(16.04) -6.84^ (61), p<0.01
^Indicates Satterthwaite t-test was used for unequal variances
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Socioeconomic status. SES varied both according to the
stocking status of the store at which the consumer was
shopping and according to the type of drug purchased
(Figure 3). Individuals buying non-ACT antimalarial
drugs at shops stocking ACTs tended to be of signifi-
cantly higher SES than those buying ACTs; those indivi-
duals purchasing ACTs where they were available paid
an average of Tsh680 (about $US 0.59) compared to an
average of Tsh936 (about $US 0.78) for other antimalar-
ial drugs (t=10.55, 1129 d.f., p<0.01).
Stocking and shopping rationales. Of individuals who
purchased ACTs at DLDB where they were available and
gave a primary reason for doing so, 23.3% (123/529) said
the drug was “most effective in treating malaria,” com-
pared to only 15.8% (92/581) who gave that rationale for
buying a non-ACT at those same DLDB (c2=9.75, 1 d.f.,
p=0.002). Individuals who said they selected a drug
because of “previous use” were much more likely to pur-
chase a non-ACT (c2=44.09, 1 d.f., p<0.01); 27.2% (158/
581) of individuals purchasing non-ACTs gave this
Table 3 Characteristics of shoppers purchasing drugs at DLDB that stocked ACTs, by drug choice
Bought antipyretic Bought
antimalarial
Bought antimalarial
other than ACT
Bought ACT
Variable n Mean(SD) n Mean(SD) t (df), p n Mean(SD) n Mean(SD) t (df), p
Age of intended
recipient (years)
465 24.00(12.32) 1002 19.34(14.27) 6.54^ (1036), p<0.01 490 22.35(13.86) 512 16.46(14.08) 6.67 (1000), p<0.01
Age of purchaser
(years)
720 28.98(8.71) 1282 30.65(8.40) -4.21 (2000), p<0.01 660 30.62(8.34) 622 30.69(8.47) -0.16 (1280), p=0.88
Education level of
purchaser (0-6)
629 2.10(1.02) 1101 2.29(1.11) -3.60^ (1404), p<0.01 562 2.29(1.11) 539 2.29(1.11) 0.01 (1099), p=0.99
Socioeconomic
status of
purchaser
720 33.78(15.01) 1285 37.05(16.92) -4.46^ (1642), p<0.01 661 38.44(17.39) 624 35.57(16.29) 3.06 (1283), p<0.01
^Indicates Satterthwaite t-test was used for unequal variances
Figure 3 Distribution of socioeconomic status by stocking status and drug choice. The distributions of SES are depicted for individuals
shopping at DLDB that were stocking and not stocking ACTs and, within those categories, by whether they purchased antipyretics, ACTs, or
non-ACT antimalarials.
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rationale compared to 11.3% (60/529) of those buying an
ACT. Price was indicated as a reason for buying ACTs for
17.20% (91/529) of customers while only 11.53% (67/581)
gave that rationale for purchasing non-ACTs (c2=7.29, 1
d.f., p<0.01). Finally, customers buying ACTs were slightly
more likely to have done so because of a recommendation
from a seller; 28.0% of ACT buyers (148/529) gave this
reason compared to 22.7% of non-ACT buyers (132/581;
c2=4.06, 1 d.f., p=0.04).
Of the two interviews conducted at DLDBs never
stocking ACTs, rationales for the lack of the subsidized
drugs included a perceived lack of demand and a lack of
knowledge:
“At first when they were establishing this shop they
were not stocking [ACTs], I think there were no custo-
mers that is why they hadn’t seen the importance of
stocking them”
-Kongwa DLDB employee
“I don’t have ACTs, because I have never been edu-
cated on them”
-Maswa DLDB owner
According to a representative from the wholesaler,
drugs were often sold to shopkeepers on credit, so
DLDB could not receive more stock until they had paid
off what they owed. Therefore, they preferred drugs and
products they could sell quickly so they could restock
and sell more. Statements citing the importance of the
speed of product movement were heard from about half
of DLDB shop owners:
“I can’t afford to sell slow moving drugs”
-Kongwa DLDB owner
Some perceptions that ACTs were a “slow moving
drug” appeared to be related to their relative novelty:
“If customers are used to SP, they will not want
ACTs”
-Maswa DLDB owner
However, promotions and advertisements on the radio
increased awareness of ACTs, and thus were perceived
to have increased the desirability for DLDB to stock
them in both Kongwa and Maswa:
“The advertisements have really persuaded the public
and they will come to the shop and ask for ACTs.”
- Kongwa DLDB owner
“Not everyone knows ACT drugs … so if they see the
posters or hear it on the radio they can come and
buy them.”
-Maswa DLDB employee
“People came to know ACTs and so they become a
fast moving drug.”
-Maswa wholesaler
Discussion
The results of this investigation both highlight the
potential for a subsidy introduced at the top of the pri-
vate sector supply chain to greatly increase access to
effective antimalarial drugs and underscore its reliance
upon existing supply chains that currently do not reach
all individuals in rural regions. Subsidized drugs were
purchased by a majority of customers shopping at stores
that stocked them [4] yet disparities in the accessibility
of ACTs persisted. As this model is scaled-up to a
national level across Africa, it is clear that a deeper
understanding of antimalarial drug supply chains and
additional interventions that target their behavior will be
needed in order to achieve the goal of dramatically
increasing ACT access among all those obtaining treat-
ment at private shops.
The two most popular products besides ACTs,
although from the same general drug class, manifested
widely different stocking patterns. Malafin stocking dis-
played highly similar geographic patterning to the subsi-
dized ACTs, while stocking of Orodar did not vary by
remoteness. There were thus potentially identifiable fac-
tors that enabled Orodar to reach rural populations
more consistently and equitably than Malafin or subsi-
dized ACTs. Within one year, more shops in the study
area stocked the subsidized ACTs than the established
products Malafin and Orodar, yet it remains unclear
whether subsidized ACTs can rise to the generalized
geographic availability of Orodar given more time.
Alternatively, the observed differences may be due to
fundamentally dissimilar delivery or promotional
mechanisms that must be overcome. This understanding
is particularly critical for the scale-up of the subsidy
since the independent evaluation of the first phase of
the AMFm will be of a similarly short time period (less
than 18 months of implementation) and thus will be
unable to decipher the role of medium- or long-term
market factors.
It is possible that different supply chains played an
important role in the different patterns observed, though
specific characteristics were not captured by this study.
Statements by interviewed shopkeepers confirmed that
the same wholesaler who distributed the subsidized
ACTs was also distributing Malafin, although it is
unknown whether Orodar was sold through the same
channels. Price was undoubtedly also a driver: Orodar is
a significantly cheaper product (exit interviewees paid
an average of 778.3 TSh for Orodar compared to
965.9 TSh for Malafin). Counter to local opinion that
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locally-produced drugs are available more broadly than
international ones, Malafin is manufactured in Tanzania
while Orodar is produced in Kenya. No data are avail-
able on other potential contributing factors including
comparative marketing of the products or the amount
of time each has been available on the market. Broader
analysis of existing supply chains and antimalarial
brands should be a priority in preparing for and asses-
sing the scale-up of the subsidy through the AMFm.
Even if subsidized ACTs are able to achieve the
reach of Orodar, this analysis suggests that there will
be a set of very remote outlets that will be particu-
larly challenging to consistently supply. While shops
that never stocked ACTs or SP were a small minority
(9/226, 4.0%), they may serve an important role in
treating individuals in the most remote areas, distri-
buting an average of 16.2 doses of antimalarials per
month. Of 24 individuals buying drugs for fever who
were captured by exit interviews, 18 (75.0%) bought
antipyretic drugs, and they were poorer than those
shopping elsewhere (t=9.01, 26 d.f., p<0.01). The
available data indicate two potential causes for the
inconsistent supply to these shops. First, they are
more remote, more than twice as far, on average,
from public health or NGO facilities. Second, they
were in operation less, existing in an average of 1.4
surveys compared to 2.7 for other shops (t=3.29, 224
d.f., p<0.01). Both have important implications for
potential interventions to reach these shops and their
customers; the first suggests the need for supplemen-
tation of the inherent market incentives for reaching
these areas [17], while the second demonstrates the
potential for increased frequency of education [18]
and product promotion activities [10].
Several DLDB owners indicating that they did not
stock ACTs due to a lack of familiarity with the pro-
duct. Education programs or advertisements thus could
play an important role in improving this component of
the supply chain [18]. However, shops in this study were
found to open and close with great frequency – only
32% were always surveyed, and nearly a quarter were
surveyed only once. Shops that were not observed con-
sistently open for business throughout the year likely
were unstable, smaller, and had more volatile stocks.
These unstable shops were less likely to stock all of the
observed antimalarials, including ACTs. The transitory
nature of these shops will make it difficult to provide
their owners with the necessary training and education
surrounding ACTs, so programs supporting the AMFm
may need to consider repeated or periodic programs
rather than one-time approaches. Alternatively, it may
be more effective to increase access to the formal public
sector or engage community health workers in such
remote regions [19].
Customers who bought ACTs when given the oppor-
tunity to do so were significantly more likely to state
that the drugs were most effective, while those who
bought non-ACTs were more likely to explain that they
preferred to buy familiar medications. These results
indicate that education and advertising interventions
may prove successful in increasing the probability that
customers will buy ACTs when given the opportunity,
and ACT purchasing may increase over time without
further intervention as individuals become accustomed
to the product. The SES of individuals who chose to
purchase ACTs when they were stocked was found
to be slightly lower than that for individuals choosing to
purchase other antimalarial drugs. This difference is
attributable to the lower price of the subsidized drugs,
which likely made them more accessible. It is important
to note that even the less rural individuals reached by
this intervention were still quite poor. The majority of
customers (72.9%) who succeeded in purchasing ACTs
only completed primary school, and these regions are
below the national average for key indicators like the
percent of households connected to the electricity grid
or receiving piped water [7]. It is likely that a similar
subsidy may prove even more effective in wealthier,
more urban districts.
This analysis has a number of limitations. First, this
investigation sought only to examine whether an
AMFm-like subsidy would succeed in improving access
to ACTs equitably, but it was not designed to evaluate
whether such a subsidy constitutes the most appropriate
approach; for example, controversy over whether the
AMFm will complement the public health system or
divert patients from it [20] is not addressed here. This
study broadly attempted to capture the most critical
variables known to influence drug usage, but it is possi-
ble that other important factors were not encompassed.
Only DLDB were included in this analysis, so other
informal private sector actors were not captured; how-
ever, previous studies have indicated that these informal
shops are less important sources of anti-malarials in
rural Tanzania [21]. The four follow-up surveys of
stocking and sales represent only snapshots and as such
cannot capture the dynamic nature of patterning. For
example, there was enormous turn-over in the DLDB
that were found to exist over the course of the year;
about a quarter of DLDB only existed during a single
survey. Finally, it is possible that the repeated interviews
of shop-keepers to assess stocking and sales may have
influenced their decision-making, although the absence
of ACT uptake in the control district indicates that this
bias is unlikely to affect qualitative interpretation of
these results. Nevertheless, the patterns observed here
provide insight into how a number of varied factors may
interact to influence the potential successes and
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challenges that may occur following the launch of the
global ACT subsidy.
Conclusions
This research indicates that scale-up of an ACT subsidy
to national or global levels has the potential to increase
ACT uptake in poor rural areas, but spatial and socioe-
conomic variation is likely to remain in stocking and
sales. Given the launch of the AMFm in 2010, and its
potential to effect unprecedented changes in the private
sector antimalarial market, it is vital to improve under-
standing of how these drugs will flow through existing
supply chains. In-depth analysis of essential differences
in the distribution and use of the most commonly avail-
able alternative products such as those discussed here
should begin immediately. These results engender cau-
tious optimism that the subsidy will succeed in adding
effective drugs into the marketplace at prices in line
with older medications, but they emphasize the need to
better understand if and how supply chains will need to
be augmented or supplemented in order to optimize the
impact of the initiative. Performing spatial analyses like
those conducted here on an ongoing basis as a compo-
nent of the monitoring and evaluation of the AMFm
may help ensure that inequities in access to treatment
are recognized and addressed.
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